Moolec Science SA Price & Performance (MLEC)

Moolec Science faces potential delisting from Nasdaq due to its stock consistently trading below $1. The company, ineligible for an additional compliance period, has proposed a reverse share split to address the issue. An appeal has temporarily delayed delisting, but the outcome remains uncertain as financial hurdles persist.12

To prevent Nasdaq delisting, Moolec Science’s board has called an extraordinary shareholders meeting to vote on a reverse share split. The move aims to boost the stock price above Nasdaq's $1 minimum threshold. However, concerns remain over the company's financial stability and its ability to meet equity requirements.32

Despite proposing a reverse share split, Moolec Science struggles with significant financial challenges, including a negative EBITDA and insufficient stockholders' equity. The delisting appeal offers temporary relief, but long-term compliance with Nasdaq rules remains in jeopardy without addressing underlying financial weaknesses.24